DK3093022T3 - Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma - Google Patents

Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma Download PDF

Info

Publication number
DK3093022T3
DK3093022T3 DK15001472T DK15001472T DK3093022T3 DK 3093022 T3 DK3093022 T3 DK 3093022T3 DK 15001472 T DK15001472 T DK 15001472T DK 15001472 T DK15001472 T DK 15001472T DK 3093022 T3 DK3093022 T3 DK 3093022T3
Authority
DK
Denmark
Prior art keywords
astma
gata
inhibitors
driven
treatment
Prior art date
Application number
DK15001472T
Other languages
English (en)
Inventor
Joachim Bille
Jonas Renz
Original Assignee
Sterna Biologicals Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterna Biologicals Gmbh & Co Kg filed Critical Sterna Biologicals Gmbh & Co Kg
Application granted granted Critical
Publication of DK3093022T3 publication Critical patent/DK3093022T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15001472T 2015-05-15 2015-05-15 Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma DK3093022T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001472.8A EP3093022B1 (en) 2015-05-15 2015-05-15 Gata-3 inhibitors for use in the treatment of th2-driven asthma

Publications (1)

Publication Number Publication Date
DK3093022T3 true DK3093022T3 (da) 2019-11-04

Family

ID=53274335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15001472T DK3093022T3 (da) 2015-05-15 2015-05-15 Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma

Country Status (16)

Country Link
US (1) US10487325B2 (da)
EP (1) EP3093022B1 (da)
JP (1) JP2018515611A (da)
KR (1) KR20180004816A (da)
CN (2) CN115137827A (da)
AU (1) AU2016264772B2 (da)
BR (1) BR112017024394A2 (da)
CA (1) CA2985858C (da)
DK (1) DK3093022T3 (da)
ES (1) ES2753436T3 (da)
HU (1) HUE046190T2 (da)
PL (1) PL3093022T3 (da)
PT (1) PT3093022T (da)
RU (1) RU2720988C2 (da)
SI (1) SI3093022T1 (da)
WO (1) WO2016184556A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463388B1 (en) * 2016-05-24 2024-09-11 Emory University Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders
EP3501607A1 (de) * 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
EP3603617A1 (de) * 2018-07-30 2020-02-05 Sterna Biologicals GmbH & Co. KG Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung
EP3805242A1 (en) * 2019-10-07 2021-04-14 Sterna Biologicals GmbH & Co. KG Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma
US11976282B2 (en) 2020-06-23 2024-05-07 Qatar University GATA3 inhibitors for the promotion of subcutaneous fat deposition
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010072475A (ko) 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 dna자임 및 치료 방법
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
WO2000051621A1 (en) 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
AUPQ201499A0 (en) 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
TWI322690B (en) * 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
DE102010007562A1 (de) * 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten

Also Published As

Publication number Publication date
WO2016184556A1 (en) 2016-11-24
PL3093022T3 (pl) 2020-02-28
JP2018515611A (ja) 2018-06-14
CA2985858C (en) 2023-10-10
AU2016264772A1 (en) 2017-11-16
ES2753436T3 (es) 2020-04-08
US20190062737A1 (en) 2019-02-28
AU2016264772B2 (en) 2021-09-09
CA2985858A1 (en) 2016-11-24
EP3093022B1 (en) 2019-08-07
HUE046190T2 (hu) 2020-02-28
US10487325B2 (en) 2019-11-26
KR20180004816A (ko) 2018-01-12
SI3093022T1 (sl) 2019-12-31
RU2720988C2 (ru) 2020-05-15
EP3093022A1 (en) 2016-11-16
CN107771082A (zh) 2018-03-06
BR112017024394A2 (pt) 2018-07-24
RU2017143014A (ru) 2019-06-17
NZ736807A (en) 2024-08-30
CN115137827A (zh) 2022-10-04
RU2017143014A3 (da) 2019-10-25
PT3093022T (pt) 2019-11-11

Similar Documents

Publication Publication Date Title
NO2025025I1 (no) Lazertinib in all its forms protected by the basic patent
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
IL280863A (en) Autotaxin inhibitors and uses thereof
IL251972B (en) Analyzing and utilizing landscapes
SI3221363T1 (sl) Protitelesa proti CD73 in njihova uporaba
SI3307322T1 (sl) Humanizirana protitelesa proti CD40 in njihove uporabe
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3149345T (lt) Būdas dviem objektams sujungti
LT3160952T (lt) Histono demetilazės inhibitoriai
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
IL243728A0 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
DK3230318T3 (da) Immune checkpoint-inhibitor-kombinationer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
IL246131A0 (en) Purge apparatus and purge method
IL251904B (en) Apilimod for use in the treatment of melanoma
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi
EP3137649C0 (en) METALLIZATION OF SURFACES
FI20150258A7 (fi) Laite veden puhdistamiseksi ja sen käyttö
ITUB20152292A1 (it) Accorgimenti per incastonare pietre e solitari.
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf
DK3102209T3 (da) Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet